Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05641831 · ClinicalTrials.gov registry record · Phase 2
Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study
A Phase 2 study of Clonal Cytopenia of Undetermined Significance, sponsored by Uma Borate.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 6
- Study locations
NCT05641831 is a Phase 2 study of Clonal Cytopenia of Undetermined Significance that is actively recruiting participants, run by Uma Borate. The registered enrollment target is 110 participants, below the 426-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (74% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT05641831, a Phase 2 study of Clonal Cytopenia of Undetermined Significance, is actively recruiting participants, sponsored by Uma Borate.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets. In patients with CCUS, blood counts have been low for a long period of time. Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop. The combination of genetic mutations and low blood cell counts puts patients with CCUS at a higher risk to develop blood cancers in the future. This transformation from low blood cell counts to cancer may be caused by inflammation in the body. Canakinumab is a monoclonal antibody that may block inflammation in the body by targeting a specific antibody called the anti-human interleukin-1beta (IL-1beta).
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- DRUG Canakinumab
- PROCEDURE Chest Radiography
- PROCEDURE Bone Marrow Aspiration and Biopsy
- PROCEDURE Echocardiography
Study Locations (6)
New York
- Weill Cornell Medical College - New York
- Memorial Sloan Kettering Cancer Center - New York
Florida
- University of Miami - Miami
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- UT Southwestern Medical Center at Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2023-02-06 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05641831
The ClinicalTrials.gov registry entry for NCT05641831 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 426-participant average among 11 other Clonal Cytopenia of Undetermined Significance trials with a reported enrollment target (74% lower). The listed sponsor is Uma Borate, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clonal Cytopenia of Undetermined Significance appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT05641831 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New York, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT05641831 about?
NCT05641831 is a clinical study titled "Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study". This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets...
What is the current status of trial NCT05641831?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2023-02-06. Estimated completion is 2028-12-31.
What conditions does trial NCT05641831 study?
This clinical trial studies the following conditions: Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT05641831?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Canakinumab (DRUG), Chest Radiography (PROCEDURE), Bone Marrow Aspiration and Biopsy (PROCEDURE), Echocardiography (PROCEDURE).
Who is sponsoring clinical trial NCT05641831?
This trial is sponsored by Uma Borate, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05641831 being conducted?
This trial has 6 study locations across Florida, New York, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clonal Cytopenia of Undetermined Significance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
RECRUITING · Phase 2
-
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RECRUITING · Phase 2
-
Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 2
-
Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.